Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Nov;83(9):1128–1135. doi: 10.1054/bjoc.2000.1413

Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer

J-P Sculier 1, J-J Lafitte 2, M Paesmans 2, J Thiriaux 2, C G Alexopoulos 2, J Baumöhl 2, J Schmerber 2, G Koumakis 2, M C Florin 2, C Zacharias 2, T Berghmans 2, P Mommen 2, V Ninane 2, J Klastersky 2
PMCID: PMC2363584  PMID: 11027424

Abstract

A phase III randomized trial was conducted in patients with metastatic NSCLC, to determine if, in association with mitomycin (6 mg m–2) and ifosfamide (3 g m–2), the combination of moderate dosages of cisplatin (60 mg m–2) and carboplatin (200 mg m–2) – CarboMIP regimen – improved survival in comparison with cisplatin (50 mg m–2) alone – MIP regimen. A total of 305 patients with no prior chemotherapy were randomized, including 297 patients assessable for survival (147 in the MIP arm and 150 in the CarboMIP arm) and 268 patients assessable for response to chemotherapy. All but eight (with malignant pleural effusion) had stage IV disease. There was a 27% (95% CI, 19–34) objective response (OR) rate to MIP (25% of the eligible patients) and a 33% (95% CI, 24–41) OR rate to CarboMIP (29% of the eligible patients). This difference was not statistically significant (P = 0.34). Duration of response was not significantly different between both arms. There was also no difference (P = 0.67) in survival: median survival times were 28 weeks (95% Cl, 24–32) for MIP and 32 weeks (95% Cl, 26–35) for CarboMIP, with respectively 1-year survival rates of 24% and 23% and 2-year survival rates of 5% and 2%. The main toxicities consisted in emesis, alopecia, leucopenia and thrombocytopenia, that were, except alopecia, significantly more severe in the CarboMIP arm. Our trial failed to demonstrate a significant improvement in response or survival when patients with metastatic NSCLC were treated, in addition to ifosfamide and mitomycin, by combination of moderate dosages of cisplatin and carboplatin instead of moderate dosage of cisplatin alone. The results support the use of a moderate dose (50 mg m–2) of cisplatin in combination with ifosfamide and mitomycin for the chemotherapy of this disease. © 2000 Cancer Research Campaign

Keywords: non-small cell lung cancer, randomized trial, cisplatin, stage IV

Full Text

The Full Text of this article is available as a PDF (96.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bonomi P. D., Finkelstein D. M., Ruckdeschel J. C., Blum R. H., Green M. D., Mason B., Hahn R., Tormey D. C., Harris J., Comis R. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol. 1989 Nov;7(11):1602–1613. doi: 10.1200/JCO.1989.7.11.1602. [DOI] [PubMed] [Google Scholar]
  2. Borges M., Sculier J. P., Paesmans M., Richez M., Bureau G., Dabouis G., Lecomte J., Michel J., Van Cutsem O., Schmerber J. Prognostic factors for response to chemotherapy containing platinum derivatives in patients with unresectable non-small cell lung cancer. (NSCLC). Lung Cancer. 1996 Dec;16(1):21–33. doi: 10.1016/s0169-5002(96)00609-5. [DOI] [PubMed] [Google Scholar]
  3. Crino L., Tonato M., Darwish S., Meacci M. L., Corgna E., Di Costanzo F., Buzzi F., Fornari G., Santi E., Ballatori E. A randomized trial fo three cisplatin-containing regimens in advanced non-small-cell lung cancer (NSCLC): a study of the Umbrian Lung Cancer Group. Cancer Chemother Pharmacol. 1990;26(1):52–56. doi: 10.1007/BF02940294. [DOI] [PubMed] [Google Scholar]
  4. Crinò L., Scagliotti G. V., Ricci S., De Marinis F., Rinaldi M., Gridelli C., Ceribelli A., Bianco R., Marangolo M., Di Costanzo F. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol. 1999 Nov;17(11):3522–3530. doi: 10.1200/JCO.1999.17.11.3522. [DOI] [PubMed] [Google Scholar]
  5. Cullen M. H., Billingham L. J., Woodroffe C. M., Chetiyawardana A. D., Gower N. H., Joshi R., Ferry D. R., Rudd R. M., Spiro S. G., Cook J. E. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol. 1999 Oct;17(10):3188–3194. doi: 10.1200/JCO.1999.17.10.3188. [DOI] [PubMed] [Google Scholar]
  6. Cullen M. H., Joshi R., Chetiyawardana A. D., Woodroffe C. M. Mitomycin, ifosfamide and cis-platin in non-small cell lung cancer: treatment good enough to compare. Br J Cancer. 1988 Sep;58(3):359–361. doi: 10.1038/bjc.1988.219. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Depierre A., Chastang C., Quoix E., Lebeau B., Blanchon F., Paillot N., Lemarie E., Milleron B., Moro D., Clavier J. Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial. Ann Oncol. 1994 Jan;5(1):37–42. doi: 10.1093/oxfordjournals.annonc.a058687. [DOI] [PubMed] [Google Scholar]
  8. Donnadieu N., Paesmans M., Sculier J. P. Chimiothérapie des cancers bronchiques non à petites cellules. Meta-analyse de la littérature en fonction de l'extension de la maladie. Rev Mal Respir. 1991;8(2):197–204. [PubMed] [Google Scholar]
  9. Einhorn L. H., Loehrer P. J., Williams S. D., Meyers S., Gabrys T., Nattan S. R., Woodburn R., Drasga R., Songer J., Fisher W. Random prospective study of vindesine versus vindesine plus high-dose cisplatin versus vindesine plus cisplatin plus mitomycin C in advanced non-small-cell lung cancer. J Clin Oncol. 1986 Jul;4(7):1037–1043. doi: 10.1200/JCO.1986.4.7.1037. [DOI] [PubMed] [Google Scholar]
  10. Elliott J. A., Ahmedzai S., Hole D., Dorward A. J., Stevenson R. D., Kaye S. B., Banham S. W., Stack B. H., Calman K. C. Vindesine and cisplatin combination chemotherapy compared with vindesine as a single agent in the management of non-small cell lung cancer: a randomized study. Eur J Cancer Clin Oncol. 1984 Aug;20(8):1025–1032. doi: 10.1016/0277-5379(84)90104-4. [DOI] [PubMed] [Google Scholar]
  11. Fuks J. Z., Aisner J., Van Echo D. A., Schipper H., Levitt M., Ostrow S., Wiernik P. H. Randomized study of cyclophosphamide, doxorubicin, and etoposide (VP16-213) with or without cisplatinum in non-small cell lung cancer. J Clin Oncol. 1983 May;1(5):295–301. doi: 10.1200/JCO.1983.1.5.295. [DOI] [PubMed] [Google Scholar]
  12. Fukuoka M., Masuda N., Furuse K., Negoro S., Takada M., Matsui K., Takifuji N., Kudoh S., Kawahara M., Ogawara M. A randomized trial in inoperable non-small-cell lung cancer: vindesine and cisplatin versus mitomycin, vindesine, and cisplatin versus etoposide and cisplatin alternating with vindesine and mitomycin. J Clin Oncol. 1991 Apr;9(4):606–613. doi: 10.1200/JCO.1991.9.4.606. [DOI] [PubMed] [Google Scholar]
  13. Gandara D. R., Crowley J., Livingston R. B., Perez E. A., Taylor C. W., Weiss G., Neefe J. R., Hutchins L. F., Roach R. W., Grunberg S. M. Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group. J Clin Oncol. 1993 May;11(5):873–878. doi: 10.1200/JCO.1993.11.5.873. [DOI] [PubMed] [Google Scholar]
  14. Giaccone G., Splinter T. A., Debruyne C., Kho G. S., Lianes P., van Zandwijk N., Pennucci M. C., Scagliotti G., van Meerbeeck J., van Hoesel Q. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol. 1998 Jun;16(6):2133–2141. doi: 10.1200/JCO.1998.16.6.2133. [DOI] [PubMed] [Google Scholar]
  15. Gralla R. J., Casper E. S., Kelsen D. P., Braun D. W., Jr, Dukeman M. E., Martini N., Young C. W., Golbey R. B. Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules. Ann Intern Med. 1981 Oct;95(4):414–420. doi: 10.7326/0003-4819-95-4-414. [DOI] [PubMed] [Google Scholar]
  16. Grilli R., Oxman A. D., Julian J. A. Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough? J Clin Oncol. 1993 Oct;11(10):1866–1872. doi: 10.1200/JCO.1993.11.10.1866. [DOI] [PubMed] [Google Scholar]
  17. Jaakkimainen L., Goodwin P. J., Pater J., Warde P., Murray N., Rapp E. Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer. J Clin Oncol. 1990 Aug;8(8):1301–1309. doi: 10.1200/JCO.1990.8.8.1301. [DOI] [PubMed] [Google Scholar]
  18. Kawahara M., Furuse K., Kodama N., Yamamoto M., Kubota K., Takada M., Negoro S., Kusunoki Y., Matui K., Takifuji N. A randomized study of cisplatin versus cisplatin plus vindesine for non-small cell lung carcinoma. Cancer. 1991 Aug 15;68(4):714–719. doi: 10.1002/1097-0142(19910815)68:4<714::aid-cncr2820680408>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  19. Klastersky J., Sculier J. P., Bureau G., Libert P., Ravez P., Vandermoten G., Thiriaux J., Lecomte J., Cordier R., Dabouis G. Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small-cell lung cancer. Lung Cancer Working Party, Belgium. J Clin Oncol. 1989 Aug;7(8):1087–1092. doi: 10.1200/JCO.1989.7.8.1087. [DOI] [PubMed] [Google Scholar]
  20. Klastersky J., Sculier J. P., Lacroix H., Dabouis G., Bureau G., Libert P., Richez M., Ravez P., Vandermoten G., Thiriaux J. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861. J Clin Oncol. 1990 Sep;8(9):1556–1562. doi: 10.1200/JCO.1990.8.9.1556. [DOI] [PubMed] [Google Scholar]
  21. Klastersky J., Sculier J. P., Ravez P., Libert P., Michel J., Vandermoten G., Rocmans P., Bonduelle Y., Mairesse M., Michiels T. A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small-cell lung carcinoma. J Clin Oncol. 1986 Dec;4(12):1780–1786. doi: 10.1200/JCO.1986.4.12.1780. [DOI] [PubMed] [Google Scholar]
  22. Le Chevalier T., Brisgand D., Douillard J. Y., Pujol J. L., Alberola V., Monnier A., Riviere A., Lianes P., Chomy P., Cigolari S. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol. 1994 Feb;12(2):360–367. doi: 10.1200/JCO.1994.12.2.360. [DOI] [PubMed] [Google Scholar]
  23. Luedke D. W., Einhorn L., Omura G. A., Sarma P. R., Bartolucci A. A., Birch R., Greco F. A. Randomized comparison of two combination regimens versus minimal chemotherapy in nonsmall-cell lung cancer: a Southeastern Cancer Study Group Trial. J Clin Oncol. 1990 May;8(5):886–891. doi: 10.1200/JCO.1990.8.5.886. [DOI] [PubMed] [Google Scholar]
  24. Marino P., Pampallona S., Preatoni A., Cantoni A., Invernizzi F. Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature. Chest. 1994 Sep;106(3):861–865. doi: 10.1378/chest.106.3.861. [DOI] [PubMed] [Google Scholar]
  25. Meert A. P., Berghmans T., Branle F., Lemaître F., Mascaux C., Rubesova E., Vermylen P., Paesmans M., Sculier J. P. Phase II and III studies with new drugs for non-small cell lung cancer: a systematic review of the literature with a methodology quality assessment. Anticancer Res. 1999 Sep-Oct;19(5C):4379–4390. [PubMed] [Google Scholar]
  26. Mylonakis N., Tsavaris N., Bacoyiannis C., Karvounis N., Kakolyris S., Karabelis A., Beer M., Kosmidis P. A randomized prospective study of cisplatin and vinblastine versus cisplatin, vinblastine and mitomycin in advanced non-small cell lung cancer. Ann Oncol. 1992 Feb;3(2):127–130. doi: 10.1093/oxfordjournals.annonc.a058127. [DOI] [PubMed] [Google Scholar]
  27. Paesmans M., Sculier J. P., Libert P., Bureau G., Dabouis G., Thiriaux J., Michel J., Van Cutsem O., Sergysels R., Mommen P. Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. J Clin Oncol. 1995 May;13(5):1221–1230. doi: 10.1200/JCO.1995.13.5.1221. [DOI] [PubMed] [Google Scholar]
  28. Paesmans M., Sculier J. P., Libert P., Bureau G., Dabouis G., Thiriaux J., Michel J., Van Cutsem O., Sergysels R., Mommen P. Response to chemotherapy has predictive value for further survival of patients with advanced non-small cell lung cancer: 10 years experience of the European Lung Cancer Working Party. Eur J Cancer. 1997 Dec;33(14):2326–2332. doi: 10.1016/s0959-8049(97)00325-0. [DOI] [PubMed] [Google Scholar]
  29. Robert F., Omura G. A., Birch R., Krauss S., Oldham R. Randomized phase III comparison of three doxorubicin-based chemotherapy regimens in advanced non-small cell lung cancer: a Southeastern Cancer Study Group trial. J Clin Oncol. 1984 May;2(5):391–395. doi: 10.1200/JCO.1984.2.5.391. [DOI] [PubMed] [Google Scholar]
  30. Rosso R., Salvati F., Ardizzoni A., Gallo Curcio C., Rubagotti A., Belli M., Castagneto B., Fusco V., Sassi M., Ferrara G. Etoposide versus etoposide plus high-dose cisplatin in the management of advanced non-small cell lung cancer. Results of a prospective randomized FONICAP trial. Italian Lung Cancer Task Force. Cancer. 1990 Jul 1;66(1):130–134. doi: 10.1002/1097-0142(19900701)66:1<130::aid-cncr2820660123>3.0.co;2-p. [DOI] [PubMed] [Google Scholar]
  31. Sculier J. P., Klastersky J., Giner V., Bureau G., Thiriaux J., Dabouis G., Efremidis A., Ries F., Berchier M. C., Sergysels R. Phase II randomized trial comparing high-dose cisplatin with moderate-dose cisplatin and carboplatin in patients with advanced non-small-cell lung cancer. European Lung Cancer Working Party. J Clin Oncol. 1994 Feb;12(2):353–359. doi: 10.1200/JCO.1994.12.2.353. [DOI] [PubMed] [Google Scholar]
  32. Sculier J. P., Paesmans M., Bureau G., Giner V., Lecomte J., Michel J., Berchier M. C., Van Cutsem O., Küstner U., Kroll F. Randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small-cell lung cancer. European Lung Cancer Working Party. J Clin Oncol. 1996 Aug;14(8):2337–2344. doi: 10.1200/JCO.1996.14.8.2337. [DOI] [PubMed] [Google Scholar]
  33. Sculier J. P., Paesmans M., Bureau G., Giner V., Lecomte J., Michel J., Berchier M. C., Van Cutsem O., Küstner U., Kroll F. Randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small-cell lung cancer. European Lung Cancer Working Party. J Clin Oncol. 1996 Aug;14(8):2337–2344. doi: 10.1200/JCO.1996.14.8.2337. [DOI] [PubMed] [Google Scholar]
  34. Sculier J. P., Paesmans M., Libert P., Bureau G., Dabouis G., Thiriaux J., Michel J., Van Cutsem O., Schmerber J., Giner V. Long-term survival after chemotherapy containing platinum derivatives in patients with advanced unresectable non-small cell lung cancer. European Lung Cancer Working Party. Eur J Cancer. 1994;30A(9):1342–1347. doi: 10.1016/0959-8049(94)90184-8. [DOI] [PubMed] [Google Scholar]
  35. Shinkai T., Eguchi K., Sasaki Y., Tamura T., Ohe Y., Kojima A., Oshita F., Saijo N. A randomised clinical trial of vindesine plus cisplatin versus mitomycin plus vindesine and cisplatin in advanced non-small cell lung cancer. Eur J Cancer. 1991;27(5):571–575. doi: 10.1016/0277-5379(91)90220-8. [DOI] [PubMed] [Google Scholar]
  36. Shinkai T., Saijo N., Eguchi K., Sasaki Y., Tominaga K., Sakurai M., Suga J., Miyaoka H., Sano T., Keicho N. Cisplatin and vindesine combination chemotherapy for non-small cell lung cancer: a randomized trial comparing two dosages of cisplatin. Jpn J Cancer Res. 1986 Aug;77(8):782–789. [PubMed] [Google Scholar]
  37. Souquet P. J., Chauvin F., Boissel J. P., Cellerino R., Cormier Y., Ganz P. A., Kaasa S., Pater J. L., Quoix E., Rapp E. Polychemotherapy in advanced non small cell lung cancer: a meta-analysis. Lancet. 1993 Jul 3;342(8862):19–21. doi: 10.1016/0140-6736(93)91882-m. [DOI] [PubMed] [Google Scholar]
  38. Thongprasert S., Sanguanmitra P., Juthapan W., Clinch J. Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy. Lung Cancer. 1999 Apr;24(1):17–24. doi: 10.1016/s0169-5002(99)00017-3. [DOI] [PubMed] [Google Scholar]
  39. Weick J. K., Crowley J., Natale R. B., Hom B. L., Rivkin S., Coltman C. A., Jr, Taylor S. A., Livingston R. B. A randomized trial of five cisplatin-containing treatments in patients with metastatic non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol. 1991 Jul;9(7):1157–1162. doi: 10.1200/JCO.1991.9.7.1157. [DOI] [PubMed] [Google Scholar]
  40. Wozniak A. J., Crowley J. J., Balcerzak S. P., Weiss G. R., Spiridonidis C. H., Baker L. H., Albain K. S., Kelly K., Taylor S. A., Gandara D. R. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol. 1998 Jul;16(7):2459–2465. doi: 10.1200/JCO.1998.16.7.2459. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES